

Claims:

1. A substituted cinnamamide compound, having the following structural formula:



M2.

2. An antidepressant and anxiolytic compound, having the following structural formula:



M2.

3. The compound according to claim 1 or 2, wherein the compound is present in a form of a solvate.

4. The compound according to claim 1 or 2, wherein the compound is present in a form of a pharmaceutically acceptable salt.


5. A pharmaceutical composition comprising the compound according to any one of claims 1-4.

6. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is in any doseable pharmaceutical form; optionally, the pharmaceutical form is selected from: tablets, capsules, oral liquids, oral lozenge, granules, pills, pulvises, pastes, pellets, suspensions, powders, solutions, injections, suppositories, soft ointments, hard ointments, creams, sprays, drops and patches; the tablets are optionally sugar-coated tablets, film-coated tablets or enteric-coated tablets; the capsules are optionally hard capsules or soft capsules; and the injections are optionally one of injection fluids, freeze-dried powder injections and liquid drug

injections.

7. The pharmaceutical composition according to claim 5, wherein when in use, the pharmaceutical composition is used in combination with other antidepressant drugs or anxiolytic drugs, or the pharmaceutical composition further comprises another antidepressant drug or anxiolytic drug; the other antidepressant drug or anxiolytic drug being selected from: nefazodone, sulpiride, alprazolam, lorazepam, buspirone, tandospirone, methylphenidate, fluoxetine, paroxetine, sertraline, citalopram, lexapro, fluvoxamine, reboxetine, venlafaxine, flupenthixol, melitracen, and Neurostan.


8. A preparation method of the compound according to claim 1 or 2, wherein the preparation method being:



Intermediate A M2

reacting (E)-3-(3',4'-methylenedioxy-5'-trifluoromethyl-phenyl)-acrylic acid (i.e. intermediate A) with NH_3 to give compound M2.

9. The preparation method of the compound according to claim 8, comprising the following reaction route:



Intermediate A M2

10. The preparation method according to claim 9, comprising the following operation steps:

dissolving (E)-3-(3',4'-methylenedioxy-5'-trifluoromethyl-phenyl)-acrylic acid (i.e. intermediate A) in dichloromethane, adding a catalytic amount of N,N-dimethylformamide, dropping oxalyl chloride under ice bath, stirring at room temperature until the completion of reaction of raw materials; concentrating and drying the reaction liquid, then adding

dichloromethane to dissolve, dropping ammonia water under ice bath, reacting at room temperature until the completion of the reaction; and removing the solvent by evaporation under reduced pressure, then adding dilute hydrochloric acid to adjust it to be acidic, precipitating a solid, filtering and rinsing it with water to obtain a crude product, which is then subjected to silica gel column chromatography for purification to give M2.

11. Use of the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 in a medicine.

12. Use of the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 in the preparation of an antidepressant, anxiolytic, or antidepressant and anxiolytic drug.

13. Use of the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 in combination with another antidepressant drug or anxiolytic drug, or use of the compound according to any one of claims 1-4 in combination with one or more additional antidepressant drugs or anxiolytic drugs in the preparation of an antidepressant, anxiolytic, or antidepressants and anxiolytic drug; here, the other antidepressant drugs or anxiolytic drugs, or the additional antidepressant drugs or anxiolytic drugs are selected from one or more of the following drugs for prevention and treatment of psychiatric disorders: e.g., nefazodone, sulpiride, alprazolam, lorazepam, buspirone, tandospirone, methylphenidate, fluoxetine, paroxetine, sertraline, citalopram, lexapro, fluvoxamine, reboxetine, venlafaxine, flupenthixol, melitracen, and Neurostan.

14. A method for preventing or treating psychiatric disorders, comprising administering the compound according to any one of claims 1-4 or the pharmaceutical composition according to any one of claims 5-7 to a patient in need thereof.

15. The method according to claim 14, wherein the preventing or treating psychiatric disorders is anti-depression, anti-anxiety or anti-depression and anti-anxiety.